Delivery Order SPE2DB20D3103-SPE2DB22FM8A1
- Not listed
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is a delivery order valued at $7,152.41 for the supply of RESTASIS 0.05% eye emulsion. The contract was awarded by the Defense Logistics Agency (DLA) and has a completion date of September 9, 2021. This delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00 that Cencora, Inc. holds with the DLA Troop Support Medical. This IDC serves as the primary vehicle...
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is a delivery order valued at $5,114.52 for the supply of RESTASIS 0.05% eye emulsion. The contract was awarded by the Defense Logistics Agency (DLA), a defense agency, and has an ultimate completion date of August 10, 2021. The contract is a firm-fixed-price delivery order, and there is no set-aside designation. This award is part of a larger Indefinite Delivery Contract (IDC) valued at up to...
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is a Delivery Order valued at $2,426.88 for the supply of RESTASIS 0.05% eye emulsion. The award was made on January 5, 2023 by the Defense Logistics Agency (DLA), a defense agency, with a performance period ending on January 6, 2023. The contract is a Firm Fixed Price Delivery Order issued under a larger Indefinite Delivery Contract (IDC) that Cencora, Inc. holds with the DLA Troop Support Medical, valued...
- This federal contract award is to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., for the delivery of RESTASIS 0.05% eye emulsion to the Defense Logistics Agency (DLA). The award, valued at $1,721.00, is a delivery order under an Indefinite Delivery Contract (IDC) held by Cencora, Inc. with the DLA Troop Support Medical, which has a total potential value of $999,999,999.00 and runs through November 2026. The contract is for the provision of a wide range of pharmaceutical products and...
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is a delivery order valued at $13,499.89 for the supply of RESTASIS 0.05% eye emulsion. The contract was awarded by the Defense Logistics Agency (DLA), a defense agency, without any set-aside designation, indicating open competition. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as the primary vehicle for the company...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract, valued at $2,171.46, is for the delivery of RESTASIS 0.05% eye emulsion, a specialty pharmaceutical product, with a completion date of December 15, 2023. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) held by Cencora, Inc. with the DLA Troop Support Medical, valued at up to $999,999,999.00 and running...
- This federal contract award is a delivery order issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is for the delivery of RESTASIS 0.05% eye emulsion, a specialty pharmaceutical product, with a ceiling value of $10,033.92 and a completion date of October 25, 2023. This contract is part of a larger Indefinite Delivery Contract (IDC) that Cencora, Inc. holds with the DLA Troop Support Medical, valued at up to $999,999,999.00...
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is a delivery order valued at $8,178.12 for the supply of RESTASIS 0.05% eye emulsion. The award was made by the Defense Logistics Agency (DLA), a defense agency, and has an ultimate completion date of January 23, 2023. The contract is a firm-fixed-price delivery order and does not have a set-aside designation, indicating open competition. Amerisourcebergen Drug Corp is a major pharmaceutical distributor...
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is a delivery order valued at $2,239.80 for the supply of Restasis 0.05% eye emulsion. The contract was awarded by the Defense Logistics Agency (DLA), a component of the Department of Defense, and has an ultimate completion date of June 6, 2023. The contract is a firm fixed-price type, and there is no set-aside designation. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract...
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is a delivery order worth $11,669.94 for the supply of RESTASIS 0.05% eye emulsion. The contract was awarded by the Defense Logistics Agency (DLA), a defense agency, and has an ultimate completion date of April 14, 2022. The contract is a firm fixed-price Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 and running through December 2025. This IDC serves...
- SPE2DB20D3103Indefinite Delivery Contract
- SPE2DB20D3103-SPE2DB22FM8A1Delivery Order
This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is a delivery order valued at $5,149.03 for the supply of RESTASIS 0.05% eye emulsion. The contract was awarded on February 28, 2022, by the Defense Logistics Agency (DLA), a defense agency of the U.S. government. The award is part of a larger Indefinite Delivery Contract (IDC) held by Cencora, Inc. with the DLA Troop Support Medical, valued at up to $999,999,999.00 and running through December 2025. This single-award IDC serves as the primary vehicle for Cencora, Inc. to deliver a comprehensive range of pharmaceutical products and medical supplies to DLA facilities supporting the Department of Defense worldwide. The contract does not have a set-aside designation, indicating open competition.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.1k | 2/28/22 |